MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
Only For Our Loyal Equitymaster Members
A Special Gift on Hidden
Treasure's 15th Anniversary
- Home
- Stock Quote (indian pharma)
- GLENMARK PHARMA
GLENMARK PHARMA Share Price 
(GLPH)
Here is the latest stock price and chart of GLENMARK PHARMA. For more details, see the GLENMARK PHARMA company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Jan 27, 2023 03:32:00 PM | ||
|---|---|---|---|
| Price (Rs)383.05 | Open (Rs) 399.05 | High (Rs) 405.55 | Low (Rs) 379.50 |
| % Change-4.00 | Volume 55,290 | Value (Rs) 21,178,835 | 52-Week H/L 512.70 / 348.90 |
| Live NSE Quotes | Jan 27, 2023 3:29:59 PM | ||
|---|---|---|---|
| Price (Rs)382.20 | Open (Rs) 399.00 | High (Rs) 405.75 | Low (Rs) 379.75 |
| % Change-4.17 | Volume 1,203,838 | Value (Rs) 467,221,566 | 52-Week H/L 505.50 / 348.50 |
| Change | |||||
|---|---|---|---|---|---|
| 1 Day -4.00% | 1 Month -9.54% | 3 Months -3.76% | 1 Year -19.59% | 5 Years (CAGR)* -9.25% | 10 Years (CAGR)* -2.71% |
* Compound Annual Growth Rate
| Valuation | ||||
|---|---|---|---|---|
| EPS (Rs)* 31.97 | P/E Ratio (x) 11.98 | Market Cap (Rs m) 108,084.53 | P/BV (x) 1.18 | Dividend Yield (%) 0.65 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX
PERIOD - Advanced Charts new
- Charts by TradingView
GLENMARK PHARMA Share Price Today:
GLENMARK PHARMA last traded price was down 4.0% to Rs 383.1 on the BSE. On the NSE, GLENMARK PHARMA last traded price was down 4.2% to Rs 382.2. The total volume of shares traded was 1.3 m.
Overall, the broader S&P BSE HEALTHCARE Index was up by 0.5%. And the benchmark S&P BSE SENSEX was at 59,330.9 (down 1.5%).
Over the last 30 days, the GLENMARK PHARMA share price is down 10.1%. And over the last one year, GLENMARK PHARMA share price is down 18.8%.
The current market capitalisation of GLENMARK PHARMA stands at Rs 108,084.53 m. For more information, check out the list of top 100 companies in India in terms of market cap.
As of December 2022, company promoters held 46.65% stake in GLENMARK PHARMA, with no shares having been pledged. To know more, check out the latest shareholding pattern of GLENMARK PHARMA.
What else is happening in the markets today? Dig in...
- TRACK NOW:
- Most Active Stocks Rs 0 to 10
- Most Active Stocks Rs 10 to 20
- Top Gainers Today BSE A Group
- Top Gainers Today NSE Above Rs 20
- Top Gainers Today BSE Above Rs 20
- Top Gainers Today BSE Sensex
- Top Gainers Today BSE Small Cap
- Top Gainers Today BSE 500
- Top Losers Today BSE A Group
- Most Active Stocks Rs 1 to 2
- Top Losers Today NSE Above Rs 20
- Buzzing Stocks Today
- Most Popular Stocks BSE 30
FAQs on GLENMARK PHARMA
What is the GLENMARK PHARMA share price today?
The last traded price of GLENMARK PHARMA was Rs 383.1 on the BSE, down 4.0% over the previous close. On the NSE, GLENMARK PHARMA last traded price was down 4.2% at Rs 382.2.
What is the market cap of GLENMARK PHARMA?
The current market capitalisation of GLENMARK PHARMA stands at Rs 108,085 m.
What is the Earnings per share (EPS) of GLENMARK PHARMA?
GLENMARK PHARMA had an EPS of Rs 32.0 in the latest financial year. In the most recent quarter, the company declared an EPS of Rs 9.9.
What is the PE Ratio and PB Ratio of GLENMARK PHARMA?
What is the Dividend Yield of GLENMARK PHARMA?
For the financial year 2022, GLENMARK PHARMA declared dividend amounting to Rs 2.5 per share. At the current price of Rs 383.1, this results in a dividend yield of 0.7%.
Today's Market
Sensex Today Tanks 874 Points Tracking Adani Stocks Selloff | ICICI Bank, SBI Fall 4% | 5 Reasons Why Indian Share Markets are Falling(Closing)
After opening the day marginally lower, Indian share markets witnessed a sharp selloff as the session progressed and ended deep in red.
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Multibagger Penny Stocks
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Best Small-cap Stocks to Buy
- Best Bluechip Stocks to Buy
- Guide to Penny Stocks
- How to Invest in the Share Market
- Warren Buffett - The Value Investor
- Pick the Best Multibagger Stocks
TRENDING TOPICS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.